Rare Disease Report
Physicians
Physicians
Patients & Caregivers
  • Question 1
  • Question 2
  • Question 3
  • Question 4
  • Question 5

1. Which diseases need to be ruled out when presented with a patient displaying symptoms associated with Multicentric Castleman Disease?

NEXT

2. Which of the following tests would not be helpful for differential diagnosis of Multicentric Castleman Disease?

NEXT

3. Which of the following are not characteristic of TAFRO syndrome as defined in patients with Multicentric Castleman Disease?

NEXT

4. As determined by lymph node pathology, which of the below would not indicate that the patient may have the plasmacytic variant of Multicentric Castleman Disease?

NEXT

5. What factors are considered when prescribing siltuximab, as per the FDA indication for it?

Castleman disease is a lymphoproliferative disorder involving an overgrowth of lymphatic cells, and affects nearly 5,000 patients annually. Multicentric Castleman Disease (MCD) affects multiple lymph nodes and lymphatic tissue. Symptoms commonly include night sweats, fevers, fatigue, and enlarged liver or spleen.
Current treatment options for MCD include surgery, chemotherapy and/or radiation therapy.



SYLVANTŪ (siltuximab) is indicated for the treatment of patients with Multicentric Castleman`s Disease (MCD) who are human immunodeficiency virus (HIV) negative and human herpesvirus-8 (HHV-8) negative.
Limitation of use: SYLVANTŪ was not studied in patients with MCD who are HIV positive or HHV-8 positive because SYLVANTŪ did not bind to virally produced interleukin-6 (IL-6) in a nonclinical study.
Copyright © RareDR 2013-2017 Rare Disease Communications. All Rights Reserved.